



| Catalog No. | HF610016 |
|---|---|
| Description |
Emicizumab (HF610016) is a research-grade recombinant antibody targeting Stuart factor. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Host species | Human |
| Isotype | IgG4-kappa |
| Expression system | Mammalian cells |
| Clonality | Monoclonal |
| Target | Stuart factor, Stuart-Prower factor, Coagulation factor X, F10, Plasma thromboplastin component, F9, Christmas factor, Coagulation factor IX, PTC |
| Endotoxin level | < 10 EU/mg |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | CAS: 1610943-06-0 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | Bispecific, ACE-910, RG6013, hBS910, 1610943-06-0 |
| Background | Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo. |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SEC-HPLC detection for Research Grade Emicizumab.

SDS-PAGE for Research Grade Emicizumab




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com




+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский